Efficacy and safety of azilsartan medoxomil, an angiotensin receptor blocker, in Korean patients with essential hypertension

Efficacy and safety of azilsartan medoxomil, an angiotensin receptor blocker, in Korean patients with essential hypertension

Abstract Background This was a phase 3, randomized, double-blind, placebo-controlled study. Methods Adult Korean patients with essential hypertension and a baseline mean sitting clinic systolic blood pressure (scSBP) ≥150 and ≤180 mmHg were randomized to 6-week treatment with placebo (n = 65), azils...

Full description

Bibliographic Details
Main Authors: Attila Juhasz, Jingtao Wu, Michie Hisada, Tomoka Tsukada, Myung Ho Jeong
Format: Article
Language:English
Published: BMC 2018-02-01
Series:Clinical Hypertension
Subjects:
Hypertension
Azilsartan medoxomil
Angiotensin II receptor antagonist
Blood pressure
Korea
Online Access:http://link.springer.com/article/10.1186/s40885-018-0086-4

Internet

http://link.springer.com/article/10.1186/s40885-018-0086-4

Similar Items